Nilotinib

In the US, Nilotinib (nilotinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Chronic Myelogenous Leukemia.

US matches:

• Nilotinib

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE08

CAS registry number (Chemical Abstracts Service)

0641571-10-0

Chemical Formula

C28-H22-F3-N7-O

Molecular Weight

529

Therapeutic Categories

Antineoplastic agent

Tyrosine kinase inhibitor

Chemical Names

4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide (WHO)

4-Methyl-N-[3-(4-methylmidazol-1-yl)-5-trifluormethylphenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamin)benzamid (IUPAC)

Foreign Names

• Nilotinibum (Latin)
• Nilotinib (German)
• Nilotinib (French)
• Nilotinib (Spanish)

Generic Name

• AMN-107 (IS: Novartis)

Brand Names

• Tasigna
  Novartis, Slovenia; Novartis, Australia; Novartis, Belgium; Novartis, Canada; Novartis, Switzerland; Novartis, Germany; Novartis, Denmark; Novartis, United Kingdom; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Japan; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Sweden; Novartis, United States; Novartis Europharm, Austria

International Drug Name Search

Glossary

IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.